

## 11 Literaturverzeichnis

1. Prentis, R. A., Lis, Y., Walker, S. R., Pharmaceutical innovation by the seven U.K.-owned pharmaceutical companies (1964–1984), *Br J Clin Pharmacol* 25, 387-396 (1998).
2. Merisko-Liversidge, E., Liversidge, G. G., Cooper, E. R., Nanosizing: a formulation approach for poorly-water-soluble compounds, *Eur J Pharm Sci* 18(2), 113-120. (2003).
3. Jonkman-de Vries, J. D., Flora, K. P., Bult, A., Beijnen, J. H., Pharmaceutical Development of (Investigational) Anticancer Agents for Parenteral Use - A Review, *Drug Development and Industrial Pharmacy* 22(6), 475-494 (1996).
4. Lennernas, H., Abrahamsson, B., The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension, *J Pharm Pharmacol* 57(3), 273-285. (2005).
5. Bauer, K. H., Fömming, K.-H., Führer, C., *Pharmazeutische Technologie*, Gustav Fischer Verlag Stuttgart (1997).
6. Müller, R. H., Keck, C. M., Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles, *J Biotech* 113, 151–170 (2004).
7. Kipp, J. E., The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs, *Int J Pharm* 284(1-2), 109-122. (2004).
8. Bisrat, M., Nyström, C., Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions., *Int J Pharm* 47, 223-231 (1988).
9. Kayser, O., Olbrich, C., Yardley, V., Kiderlen, A. F., Croft, S. L., Formulation of amphotericin B as nanosuspension for oral administration, *Int J Pharm* 254(1), 73-75. (2003).
10. Jia, L., Wong, H., Cerna, C., Weitman, S. D., Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry, *Pharm Res* 19(8), 1091-1096. (2002).
11. Wu, Y., et al., The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human, *Int J Pharm* 285(1-2), 135-146. (2004).
12. Gaßmann, P., List, M., Schweitzer, A., Sucker, H., Hydrosols - Alternatives for the parenteral application of poorly soluble drugs, *Eur J Pharm Biopharm* 40(2), 64-72 (1994).

13. Chen, X., Young, T. J., Sarkari, M., Williams, R. O., 3rd, Johnston, K. P., Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution, *Int J Pharm* 242(1-2), 3-14. (2002).
14. Müller, R. H., Peters, K., Becker, R., Kruss, B., Nanosuspensions for the i.v. Administration of Poorly Soluble Drugs - Stability During Sterilization and Long-Term Storage, *Intern. Symp. Control. Rel. Bioact. Mater.* 22, Seattle, 574-575 (1995).
15. Liversidge, G. G., Cundy, K., Bishop, J. F., Czekai, D. A., Surface modified drug nanoparticles United States Patent No. 5,145,684, 1992, United States Patent No. 5,145,684 (1992).
16. Liversidge, G. G., Conzentino, P., Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats, *Int J Pharm* 125, 309-313 (1995).
17. Merisko-Liversidge, E., et al., Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs, *Pharm Res* 13(2), 272-278. (1996).
18. Merisko-Liversidge, E., McGurk, S. L., Liversidge, G. G., Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn-insulin, *Pharm Res* 21(9), 1545-1553. (2004).
19. Chan, C. P., Bruemmel, Y., Seydack, M., Sin, K. K., Wong, L. W., Merisko-Liversidge, E., Trau, D., Renneberg, R., Nanocrystal biolabels with releasable fluorophores for immunoassays, *Anal Chem* 76(13), 3638-3645. (2004).
20. Buchmann, S., Fischli, W., Theil, F. P., Alex, R., Aqueous microsuspensions, an alternative intravenous formulation for animal studies, *Eur J Pharm Biopharm* 42, 10S (1996).
21. Clement, M., Huwald, E., Mahlung und Verschleiß in Trommel- und Strahlmühlen, in: S. Rumpf (Hrsg.), *Dechema-Monographien 1589-1615*, VCH Weinheim, Vol. 79/A (1976).
22. Bruno, J. A., Doty, B. D., Gustow, E., Method of grinding pharmaceutical substances, *Eur. Patent Application No. 0600528A1* (1993).
23. Müller, R. H., Böhm, B. H. L., Nanosuspensions, in: R.H. Müller, S. Benita, and B.H.L. Böhm (Hrsg.), *Emulsions and nanosuspensions for the formulation of poorly soluble drugs*, medpharm Scientific Publishers Stuttgart, 149-174 (1998).
24. Müller, R. H., Becker, R., Kruss, B., Peters, K., Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit, *Deutsche Patentanmeldung Nr. 4440337.2, US Patent 5,858,410* (1999) (1994).

25. Müller, R. H., Peters, K., Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique, *Int J Pharm* 160, 229-237 (1998).
26. DeVilliers, M. M., van der Watt, J. G., Lötter, A. P., Liebenberg, W., Dekker, T. G., Correlation between physico-chemical properties and cohesive behavior of furosemide crystal modifications, *Drug Development and Industrial Pharmacy* 21(17), 1975-1988 (1995).
27. Müller, R. H., Gohla, S., Dingler, A., Schneppe, T., Large scale production of solid lipid nanoparticles (SLN<sup>TM</sup>) and nanosuspensions (DissoCubes<sup>TM</sup>), in: D. Wise (Hrsg.), *Handbook of Pharmaceutical Controlled Release Technology*, Marcel Dekker Inc. New York, 359-376 (2000).
28. Kleinig, A. R., Middelberg, A. P. J., The correlation of cell disruption with homogenizer valve pressure gradient determined by computational fluid dynamics, *Chem Engineering Science* 51(23), 5103-5110 (1996).
29. Grau, M., Kayser, O., Müller, R. H., Nanosuspensions of poorly soluble drugs - reproducibility of small scale production, *Int J Pharm* 196, 155-157 (2000).
30. Grau, M., Untersuchungen zur Lösungsgeschwindigkeit, Sättigungslöslichkeit und Stabilität von hochdispersen Arzneistoffsuspensionen., Dissertation, Freie Universität Berlin (2000).
31. Böhm, B. H. L., Herstellung und Charakterisierung von Nanosuspensionen als neue Arzneiform für Arzneistoffe mit geringer Bioverfügbarkeit, Dissertation, Freie Universität Berlin (1999).
32. Tröster, F., Müller, R. H., Cremophor-free aqueous paclitaxel nanosuspension production and chemical stability, *Intern Symp Control Rel Bioact Mater*, Honolulu, (2004).
33. Möschwitzer, J., Achleitner, G., Pomper, H., Müller, R. H., Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology, *Eur J Pharm Biopharm* 58(3), 615-619. (2004).
34. Peters, K., Nanosuspensionen - ein neues Formulierungsprinzip für schwerlösliche Arzneistoffe, Dissertation, Freie Universität Berlin (1999).
35. Peters, K., Leitzke, S., Diederichs, J. E., Borner, K., Hahn, H., Müller, R. H., Ehlers, S., Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine *Mycobacterium avium* infection, *J Antimicrob Chemother* 45(1), 77-83. (2000).
36. Jacobs, C., Kayser, O., Müller, R. H., Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone, *Int J Pharm* 214(1-2), 3-7. (2001).

37. Jacobs, C., Muller, R. H., Production and characterization of a budesonide nanosuspension for pulmonary administration, *Pharm Res* 19(2), 189-194. (2002).
38. Ostrander, K. D., Bosch, H. W., Bondanza, D. M., An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization, *Eur J Pharm Biopharm* 48(3), 207-215. (1999).
39. Kayser, O., A new approach for targeting to *Cryptosporidium parvum* using mucoadhesive nanosuspensions: research and applications, *Int J Pharm* 214, 83-85 (2001).
40. Ponchel, G., Montisci, M.-J., Dembri, A., Durrer, C., Duchene, D., Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract, *Eur J Pharm Biopharm* 4, 25-31 (1997).
41. Müller, R. H., Mäder, K., Krause, K., Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln, Deutsche Patentanmeldung Nr. 199 32 157.4 (1999).
42. Müller, R. H., Schmidt, S., SolEmuls technology for i. v. emulsions of poorly soluble drugs: amphotericin B, 4th World Meeting ADRITELF/APV/APGI, Florence, 1451-1452 (2002).
43. Schmidt, S., Parenterale O/W-Emulsionen: Plasmaproteininteraktionen und Inkorporation von Arzneistoffen, Dissertation, Freie Universität Berlin (2002).
44. Akkar, A., Muller, R. H., Formulation of intravenous Carbamazepine emulsions by SolEmuls technology, *Eur J Pharm Biopharm* 55, 305-312 (2003).
45. Akkar, A., Muller, R. H., Intravenous itraconazole emulsions produced by SolEmuls technology, *Eur J Pharm Biopharm* 56, 29-36 (2003).
46. Müller, R. H., Böhm, B. H. L., Grau, M. J., Nanosuspensions - Formulierungen für schwerlösliche Arzneistoffe mit geringer Bioverfügbarkeit: II. Stabilität, biopharmazeutische Aspekte, mögliche Arzneiformen und Zulassungsfragen, *Pharm Ind* 61(2), 175-178 (1999).
47. Stafford, J. W., Enteric film coating using completely aqueous dissolved hydroxypropyl methyl cellulose phthalate spray solutions, *Drug Dev and Ind Pharm* 8(4), 513-530 (1982).
48. Trenktrog, T., Müller, B. W., Specht, F. M., Seifert, J., Enteric coated insulin pellets: development, drug release and in vivo evaluation, *Eur J Pharm Sci* 4, 323-329 (1996).
49. Specht, F., Saugestad, M., Waaler, T., Müller, B. W., The application of shellac as an acidic polymer for enteric coating, *Pharm Technol Europe* 10, 20-28 (1998).
50. Sun, Y. M., F., H. W., Chang, C. C., Spray-coated and solution-cast ethylcellulose pseudolatex membranes, *J Membr Sci* 157, 159-170 (1999).

51. Osterwald, H. P., Properties of film-formers and their use in aqueous systems, *Pharm Res* 2, 14-18 (1985).
52. O'Donnell, P. B., McGinity, J. W., Mechanical properties of polymeric films prepared from aqueous polymeric dispersions, in: J.W. McGinity (Hrsg.), *Aqueous polymeric coatings for pharmaceutical dosage forms*, Marcel Dekker New York, 517-548 (1997).
53. Bodmeier, R., Guo, X., Paeratukul, O., Process and formulation factors affecting the drug release from pellets coated with ethylcellulose-pseudolatex Aqua-coat, in: J.W. McGinity (Hrsg.), *Aqueous polymeric coatings for pharmaceutical dosage forms*, Merceel Dekker New York, 55-80 (1997).
54. Harris, M. R., Ghebre-Sellassie, I., Aqueous polymeric coating for modified release oral dosage forms, in: J.W. McGinity (Hrsg.), *Aqueous polymeric coatings for pharmaceutical dosage forms*, Merceel Dekker New York, 81-100 (1997).
55. Thioune, O., Briançon, S., Devissaguet, J. P., Fessi, H., Development of a New Ethylcellulose Pseudolatex for Coating, *Drug development research* 50, 157–162 (2000).
56. Lin, K. H., Lin, S. Y., Li, M. J., Compression forces and amount of outer coating layer affecting the time-controlled disintegration of the compression-coated tablets prepared by direct compression with micronized ethylcellulose, *J Pharm Sci* 90(12), 2005-2009. (2001).
57. Pearnchob, N., Bodmeier, R., Coating of pellets with micronized ethylcellulose particles by a dry powder coating technique, *Int J Pharm* 268(1-2), 1-11. (2003).
58. Pearnchob, N., Bodmeier, R., Dry polymer powder coating and comparison with conventional liquid-based coatings for Eudragit RS, ethylcellulose and shellac, *Eur J Pharm Biopharm* 56(3), 363-369. (2003).
59. Specht, F., Pseudo-Latex Verfahren zur Herstellung von Mikropartikeln und Filmen, Dissertation, Christian-Albrechts-Universität Kiel (1995).
60. Müller, B. W., Junis-Specht, F., Verfahren zur Herstellung von Pseudolatices und Mikro- oder nanopartikeln und deren Verwendung zur Herstellung von pharmazeutischen Präparaten, Deutsches Patent Nr. DE 42 44 466 (1995).
61. Krevelen, D. W. v., Eigenschaften von Polymeren, deren Abschätzung und Korrelierung mit der chemischen Struktur, Elsevier New York (1976).
62. Fahr, A., Kissel, T., Mikropartikel und Implantate: Arzneiformen zur parentaralen Applikation, in: R.H. Müller and G.E. Hildebrand (Hrsg.), *Pharmazeutische Technologie: Moderne Arzneiformen*, Wissenschaftliche Verlagsgesellschaft Stuttgart, 187-202 (1997).

63. Fischer, W., Müller, B. W., Method and apparatus for the manufacture of a product having a substance embedded in a carrier, US Patent No. 5,043,280 (1991).
64. Langley, J., Symes, K. C., Polymeric compositions and methods for producing them, European Patent No. 0 361 677 (1993).
65. Bodmeier, R., Tableting of coated pellets, Eur J Pharm Biopharm 43, 1-8 (1997).
66. Takeuchi, H., Kawashima, Y., Aqueous-based coatings and microparticles in matrix tablets, in: J.W. McGinity (Hrsg.), *Aqueous polymeric coatings for pharmaceutical dosage forms*, Marcel Dekker New York, 549-569 (1997).
67. Jahnke, S., The theory of high-pressure homogenization., in: R.H. Müller, S. Benita, and B. Böhm (Hrsg.), *Emulsions and Nanosuspensions for the formulation of poorly soluble drugs*, Medpharm Scientific Publishers Stuttgart, 177-200 (1998).
68. Lucks, J. S., Parenterale Fettesemulsionen als Arzneistoffträger - Herstellung, Charakterisierung und Stabilität, Dissertation, Christian-Albrechts-Universität Kiel (1993).
69. Zheng, J. Y., Harris, C. C., Somasundaran, P., A study on grinding and energy input in stirred media mills, Powder Technology 86(2), 171-178 (1996).
70. Müller, R. H., Mäder, K., Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art, Eur J Pharm Biopharm 50(1), 161-177 (2000).
71. Müller, R. H., Schuhmann, R., Teilchengrößenmessung in der Laborpraxis, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart (1996).
72. Müller, R. H., Zetapotential und Partikelladung in der Laborpraxis, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart (1996).
73. Rein, S., Lips, K., Schmidt, J., Materialforschung mit neuen analytischen Methoden, FVS Themen , 60-65 (2003).
74. Mäder, K., Pharmazeutische Anwendungen der Elektronenspinresonanzspektroskopie (ESR), PZ Prisma 3, 202-212 (1998).
75. Mäder, K., Untersuchungen zur Arzneistofffreisetzung aus biologisch abbaubaren Arzneiträgern in vitro und in vivo, Dissertation, Humboldt Universität Berlin (1998).
76. Jores, K., Mehnert, W., Mäder, K., Physicochemical investigations on solid lipid nanoparticles (SLN) and on oil-loaded solid lipid nanoparticles: a NMR- and ESR-study, Pharm Res accepted, (2003).
77. Mizushima, J., Kawasaki, Y., Tabohashi, T., Kitano, T., Sakamoto, K., Kawashima, M., Cooke, R., Maibach, H. I., Effect of surfactants on human stratum

- corneum: electron paramagnetic resonance study, *Int J Pharm* 197, 193-202 (2000).
78. Chow, A. H. L., Hsia, C. K., Gordon, J. D., Young, J. W. M., Vargha-Butler, E. I., Assessment of wettability and its relationship to the intrinsic dissolution rate of doped phenytoin crystals, *Int J Pharm* 126, 21-28 (1995).
  79. Fiedler, H. P., *Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete*, Editio-Cantor-Verlag Aulendorf (1996).
  80. Leu, D., Manthey, B., Kreuter, J., Speiser, P., DeLuca, P. P., Distribution and elimination of coated polymethyl(2-14C) methacrylate nanoparticles after intravenous injection in rats, *J of Pharm Sci* 73(10), 1433-1437 (1984).
  81. Hillery, A. M., T., F. A., The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60-nm polystyrene particles after oral administration in the rat., *Int J Pharm* 132, 123-130 (1996).
  82. Banker, G. S., Peck, G. E., The new water-based colloidal dispersions, *Pharm Technol* 5, 55-61 (1981).
  83. Nakagami, H., Keshikawa, T., Mastumura, M., Tsukamoto, H., Application of aqueous suspensions and latex dispersions of water-insoluble polymers for tablet and granule coatings, *Chem Pharm Bull* 39(7), 1837-1842 (1991).
  84. Wesseling, M., Bodmeier, R., Drug release from beads coated with an aqueous colloidal ethylcellulose dispersion, Aquacoat®, or an organic ethylcellulose solution, *European Journal of Pharmaceutics and Biopharmaceutics* 47, 33-38 (1999).
  85. Chopra, R., Podczek, F., Newton, J. M., Alderborn, G., The influence of pellet shape and film coating on the filling of pellets into hard shell capsules, *Eur J Pharm Biopharm* 53(3), 327-333. (2002).
  86. Siepmann, F., Siepmann, J., Walther, M., MacRae, R. J., Bodmeier, R., Blends of aqueous polymer dispersions used for pellet coating: importance of the particle size, *J Control Release* 105(3), 226-239. (2005).
  87. Nixon, J. R., Agyilirah, G. A., Effect of microcapsule core-wall ratio and aggregate size on the properties of tableted microcapsules, *J Pharm Sci* 73(1), 52-54. (1984).
  88. Tsai, T., San, Y. P., Ho, H. O., Wu, J. S., Sheu, M. T., Film-forming polymer-granulated excipients as the matrix materials for controlled release dosage forms, *J Control Release* 51(2-3), 289-299. (1998).
  89. Miller, R. A., Leung, E. M., Oates, R. J., The compression of spheres coated with an aqueous ethylcellulose dispersion, *Drug Dev Ind Pharm* 25(4), 503-511. (1999).

90. Lin, S. Y., Effect of excipients on tablet properties and dissolution behavior of theophylline-tableted microcapsules under different compression forces, *J Pharm Sci* 77(3), 229-232. (1988).
91. Agrawal, A. M., Neau, S. H., Bonate, P. L., Wet granulation fine particle ethylcellulose tablets: effect of production variables and mathematical modeling of drug release, *AAPS PharmSci* 5(2), E13. (2003).
92. Barra, J., Falson-Rieg, F., Doelker, E., Modified drug release from inert matrix tablets prepared from formulations of identical composition but different organisations, *J Control Release* 65(3), 419-428. (2000).
93. Desai, R. P., Neau, S. H., Pather, S. I., Johnston, T. P., Fine-Particle ethylcellulose as a tablet binder in direct compression, immediate-release tablets, *Drug Dev Ind Pharm* 27(7), 633-641. (2001).
94. Grattard, N., Pernin, M., Marty, B., Roudaut, G., Champion, D., Le Meste, M., Study of release kinetics of small and high molecular weight substances dispersed into spray-dried ethylcellulose microspheres, *J Control Release* 84(3), 125-135. (2002).
95. Elkharraz, K., Dashevsky, A., Bodmeier, R., Microparticles prepared by grinding of polymeric films, *J Microencapsul* 20(5), 661-673. (2003).
96. Streubel, A., Siepmann, J., Bodmeier, R., Floating microparticles based on low density foam powder, *Int J Pharm* 241(2), 279-292. (2002).
97. Lin, S., Lin, K., Li, M., Micronized ethylcellulose used for designing a directly compressed time-controlled disintegration tablet, *Journal of Controlled Release* 70, 321-328 (2001).
98. Melzer, E., Kreuter, J., Daniels, R., Ethylcellulose: a new type of emulsion stabilizer, *Eur J Pharm Biopharm* 56, 23-27 (2003).
99. Azouka, A., Huggett, R., Harrison, A., The production of shellac and its general and dental uses: a review, *J Oral Rehabil* 20(4), 393-400. (1993).
100. Penning, M. H., Schellack - ein "nachwachsender Rohstoff" mit interessanten Eigenschaften und Anwendungen, *Seifen-Öle-Fette-Wachse* 6, 221-224 (1990).
101. Pearnchob, N., Evaluation of new film coating processes and materials, Dissertation, FU Berlin Berlin (2002).
102. Cockeram, H. S., Levine, S. A., The physical and chemical properties of shellac, *J Soc Cosmetic Chem* , 316-323 (1961).
103. Vasavada, R. C., Shellac, in: A. Wade and P.J. Weller (Hrsg.), *Handbook of pharmaceutical excipients*, American Pharmaceutical Association Washington D. C., 422-423 (1994).
104. Smolinske, S. C., *Handbook of food, drug and cosmetic excipients*, CRC Press Boca Raton, Florida (1992).



105. Porter, S. C., Bruno, C. H., Coating of pharmaceutical solid-dosage forms, in: H.A. Lieberman, L. Lachman, and J.B. Schwartz (Hrsg.), *Pharmaceutical dosage forms: Tablets*, Marcel Dekker, Inc. New York, Vol. 3, 77-160 (1990).
106. Pearnchob, N., Siepmann, J., Bodmeier, R., Pharmaceutical applications of shellac: moisture-protective and taste-masking coatings and extended-release matrix tablets, *Drug Dev Ind Pharm* 29(8), 925-938. (2003).
107. Hogan, J. E., Film-coating materials and their properties, in: G. Cole, J. Hogan, and M. Aulton (Hrsg.), *Pharmaceutical coating technology*, Taylor & Francis Books, Ltd. London, 6-52 (1995).
108. Hogan, J. E., Modified release coatings, in: G. Cole, J. Hogan, and M. Aulton (Hrsg.), *Pharmaceutical coating technology*, Taylor & Francis Books, Ltd. London, 409-438 (1995).
109. Limmatvapat, S., Limmatvapat, C., Luangtana-Anan, M., Nunthanid, J., Oguchi, T., Tozuka, Y., Yamamoto, K., Puttipipatkachorn, S., Modification of physicochemical and mechanical properties of shellac by partial hydrolysis, *Int J Pharm* 278(1), 41-49 (2004).
110. Limmatvapat, S., Nunthanid, J., Luangtana-anan, M., Puttipipatkachorn, S., Effect of alkali treatment on properties of native shellac and stability of hydrolyzed shellac, *Pharm Dev Technol* 10(1), 41-46. (2005).
111. Golz-Berner, K., Zastrow, L., Wäßrige Schellacklösung oder -dispersion und Verfahren zur Herstellung, Deutsches Patent Nr. DE 19734548 (2000).
112. Krause, K. P., Muller, R. H., Production of aqueous shellac dispersions by high pressure homogenisation, *Int J Pharm* 223(1-2), 89-92. (2001).
113. Cook, R. B., Shellac dispersions and coatings, and method of forming aqueous-based shellac dispersions and coatings, US Patent No. 5,567,438 (1996).
114. Pearnchob, N., Dashevsky, A., Bodmeier, R., Improvement in the disintegration of shellac-coated soft gelatin capsules in simulated intestinal fluid, *J Control Release* 94(2-3), 313-321. (2004).
115. Qussi, B., Suess, W. G., Investigation of the effect of various shellac coating compositions containing different water-soluble polymers on in vitro drug release, *Drug Dev Ind Pharm* 31(1), 99-108. (2005).
116. Sheorey, D. S., Kshirsagar, M. D., Dorle, A. K., Study of some improved shellac derivatives as microencapsulating materials, *J Microencapsul* 8(3), 375-380. (1991).
117. Lehmann, K., In Wasser dispergierbare, hydrophile Acrylharze mit abgestufter Permeabilität für diffusionsgesteuerte Wirkstoffabgabe aus Arzneiformen, *Acta Pharm Technol* 32, 146 (1986).

118. Wheatley, T. A., Steuernagel, C. R., Latex emulsions for controlled drug delivery, in: J.W. McGinity (Hrsg.), *Aqueous polymeric coatings for pharmaceutical dosage forms*, Marcel Dekker New York, 1-54 (1997).
119. Rice, W. G., Turpin, J. A., Huang, M., Clanton, D., Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein., *Nat Med* 3(3), 341-345 (1997).
120. Goebel, F. D., Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy, *AIDS* 15, 33-45 (2000).
121. Chen, H. X., Bamberger, U., Heckel, A., Guo, X., Cheng, Y. C., BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport, *Cancer Research* 53(9), 1974-1977 (1993).
122. Jordan, B. F., Baudelet, C., Gallez, B., Carbon-centered radicals as oxygen sensors for in vivo electron paramagnetic resonance: screening for an optimal probe among commercially available charcoals, *Magma* 7(2), 121-129. (1998).
123. Atsarkin, V. A., Demidov, V. V., Vasneva, G. A., Dzheparov, F. S., Ceroke, P. J., Odintsov, B. M., Clarkson, R. B., Mechanism of oxygen response in carbon-based sensors, *J Magn Reson* 149(1), 85-89. (2001).
124. Jackson, S. K., Madhani, M., Thomas, M., Timmins, G. S., James, P. E., Applications of in vivo electron paramagnetic resonance (EPR) spectroscopy: measurements of pO<sub>2</sub> and NO in endotoxin shock, *Toxicol Lett* 120, 253-257 (2001).
125. Santini, M. T., Malorni, W., Zicari, C., Paradisi, S., Straface, E., Indovina, P. L., Fusinite as a specific probe for the determination of molecular oxygen concentration in cells, *Biochim Biophys Acta* 1243, 110-116 (1995).
126. Liu, K. J., Miyake, M., James, P. E., Swartz, H. M., Separation and enrichment of the active component of carbon based paramagnetic materials for use in EPR oximetry, *J Magn Reson* 133(2), 291-298. (1998).
127. Goldmann, S., Entdeckung der Calcium-Antagonisten, *Pharm Unserer Zeit* 34(5), 366-373 (2005).
128. Auterhoff, H., Knabe, J., Höltje, H. D., *Lehrbuch der pharmazeutischen Chemie*, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart (1994).
129. Lindenberg, M., Kopp, S., Dressman, J. B., Classification of orally administered drugs on the World Health Organisation model list of essential medicines according to the biopharmaceutics classification system, *Eur J Pharm Biopharm* 58, 265-278 (2004).
130. Schubert-Zsilavec, M., Stark, H., Medizinische Chemie der L-Typ-Calcium-Kanalblocker, *Pharm Unserer Zeit* 34(5), 374-379 (2005).

131. Dresser, G. K., Spence, J. D., Bailey, D. G., Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrom P4503A4 inhibition, *Clin Pharmacokinet* 38, 41-57 (2000).
132. Warnke, A., Blume, H., Arzneizubereitungen mit Calciumkanal-Blockern, *Pharm Unserer Zeit* 34(5), 400-410 (2005).
133. Hombreiro-Perez, M., Siepmann, J., Zinutti, C., Lamprecht, A., Ubrich, N., Hoffman, M., Bodmeier, R., Maincent, P., Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling, *J Control Release* 88(3), 413-428. (2003).
134. Kim, Y. I., Fluckiger, L., Hoffman, M., Lartaud-Idjouadiene, I., Atkinson, J., Maincent, P., The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats, *Br J Pharmacol* 120(3), 399-404. (1997).
135. Berger, C., Charakterisierung und Stabilisierung einer wäßrigen Antirheumatikasuspension zur peroralen Applikation., Dissertation, Christian-Albrecht-Universität Kiel (1994).
136. Müller, R. H., Weyhers, H., zur Mühlen, A., Dingler, A., Mehnert, W., Solid lipid nanoparticles - ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika, I. Systemeigenschaften, Herstellung und Scaling-up, *Pharm Ind* 59(5), 423-427 (1997).